Barclays analyst Andrew Mok raised the firm’s price target on HCA Healthcare to $367 from $356 and keeps an Overweight rating on the shares. The company’s Q1 results are “cleaner than investors suspect” and came in ahead of HCA’s internal plan despite a net negative calendar headwind on outpatient surgeries, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare Announces Q1 Results and Shareholder Dividend
- HCA Healthcare backs FY24 EPS view $19.70-$21.20, consensus $20.64
- HCA Healthcare reports Q1 adjusted EPS $5.36, consensus $5.01
- Options Volatility and Implied Earnings Moves Today, April 26, 2024
- Notable companies reporting before tomorrow’s open